Express Scripts's most recent trend suggests a bullish bias. One trading opportunity on Express Scripts is a Bull Put Spread using a strike $71.50 short put and a strike $66.50 long put offers a potential 26.26% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $71.50 by expiration. The full premium credit of $1.04 would be kept by the premium seller. The risk of $3.96 would be incurred if the stock dropped below the $66.50 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Express Scripts is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Express Scripts is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Express Scripts
Costs to treat common ailments a prescription for pain
Mon, 01 Feb 2016 15:04:14 GMT
Express Scripts drops coverage of Valeant diabetes drug Glumetza
Fri, 29 Jan 2016 20:45:21 GMT
Reuters – Express Scripts Holding Co , the U.S. No. 1 pharmacy benefits manager, said on Friday it would stop covering Glumetza, a diabetes drug made by Valeant Pharmaceuticals International Inc, after a generic competitor enters the market on Feb. 1. Express Scripts, which will exclude about 80 drugs from its list of covered medicines in 2016, made the addition in an announcement on its website. Valeant signed a deal with Walgreens Boots Alliance Inc late last year to sell its drugs directly to patients.
One of the biggest healthcare companies in America fired a warning shot at Valeant
Fri, 29 Jan 2016 19:16:01 GMT
Payers see price leverage with entry of Merck hepatitis C drug
Fri, 29 Jan 2016 18:40:49 GMT
Reuters – U.S. pharmacy benefit managers expect the launch of Merck & Co Inc's new hepatitis C pill to improve their leverage in price negotiations with drugmakers. The Food and Drug Administration on Thursday approved Merck's Zepatier for treatment of patients infected with the most common form of the liver-destroying virus, genotype 1, as well as the less common genotype 4. The list price for the new drug is $54,600 for a 12-week regimen – compared with $94,500 for Gilead Sciences Inc's Harvoni.
Also on Market Tamer…
Follow Us on Facebook